Top Markets
#1 Islamic Coin Islamic Coin +151.45%
#2 DOVU DOVU +50.49%
#3 Black Phoenix Black Phoenix +34.88%
#4 Velvet Velvet +32.10%
#5 Akedo Akedo +21.65%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +19.03%
#7 DoubleZero DoubleZero +15.69%
#8 Cross Cross +12.56%
#9 HOME HOME +12.51%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +12.12%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
OKYO Pharma Limited OKYO Pharma Limited

OKYO Pharma Limited

OKYO
Rank in Stocks #39874
OKYO Pharma Limited, a biopharmaceutical entity operating at the preclinical... OKYO Pharma Limited, a biopharmaceutical entity operating at the preclinical stage, focuses on creating treatments for individuals experiencing inflammatory conditions of the eye and chronic ocular pain. Established in 2007 and headquartered in London, UK, the company's primary investigational drug is OK-101, aimed at addressing dry eye syndrome. Additionally, the firm is advancing OK-201, a preclinical analogue developed from bovine adrenal medulla, designed to alleviate neuropathic ocular pain.
Share Price
$0.01904982
Last synced: 2023-05-19
Market Cap
$316.00K
Change (1 day)
-17.05%
Change (1 year)
0.00%
Country
GB
Trade OKYO Pharma Limited (OKYO)

Category

Healthcare
P/E ratio for OKYO Pharma Limited (OKYO)
P/E ratio as of 2026 TTM: 0
According to OKYO Pharma Limited latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for OKYO Pharma Limited from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.